Sandra Milligan - May 1, 2023 Form 4 Insider Report for Organon & Co. (OGN)

Role
Head of Research & Development
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Sandra Milligan
Stock symbol
OGN
Transactions as of
May 1, 2023
Transactions value $
-$20,344
Form type
4
Date filed
5/3/2023, 07:06 PM
Previous filing
Apr 4, 2023
Next filing
May 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise +1.9K +7.69% 26.6K May 1, 2023 Direct F1
transaction OGN Common Stock Tax liability -$20.3K -826 -3.1% $24.63 25.8K May 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Options Exercise $0 -1.9K -100% $0.00* 0 May 1, 2023 Common Stock 1.9K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested.